A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms

XenoPort, Inc.0 sites161 target enrollmentDecember 2008

ConditionsBack Pain

InterventionsArbaclofen placarbil, 20 mg Placebo Arbaclofen placarbil, 30 mg Arbaclofen placarbil, 40 mg

DrugsArbaclofen placarbil, 20 mg Placebo Arbaclofen placarbil, 30 mg Arbaclofen placarbil, 40 mg

Overview

Phase: Phase 2
Intervention: Arbaclofen placarbil, 20 mg
Conditions: Back Pain
Sponsor: XenoPort, Inc.
Enrollment: 161
Primary Endpoint: Incidence of treatment-emergent adverse events
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.

Registry

clinicaltrials.gov

Start Date

December 2008

End Date

July 2009

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

XenoPort, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Acute moderate to severe muscle spasms in the lumbar region, as indicated by a minimum Visual Analog Scale pain severity score of 4.0 cm, beginning either:
•within four days prior to screening for subjects who do not require a 24-hour washout
•within three days for subjects who require a 24-hour washout
•Willing to discontinue all analgesics (e.g. NSAIDS, COX-2 inhibitors, acetaminophen), aspirin \>81 mg/day, short-acting muscle relaxants (i.e. carisoprodol, Soma®), and herbal remedies for pain at least 24 hours prior to first dose and to refrain from use during the study (cardio-protective doses of aspirin ≤ 81 mg /day are allowed).

Exclusion Criteria

•Clinically significant abnormal neurological history or examination at screening (excluding back spasm), including lumbar radicular symptoms, spinal stenosis, foot drop, herniated nucleus pulposus, or other structural defects
•Subjects with back spasm related to major trauma to the region
•Subjects with muscle spasms due to a work-related injury or subjects involved in any injury-related litigation
•Subjects using any of the following medications at screening:
•Opioids, both short- and long-acting including but not limited to: morphine, fentanyl patch, oxycodone, tramadol)
•benzodiazepines, such as valium and lorazepam
•cyclobenzaprine containing drugs (e.g., Flexeril, Amrix)
•carisoprodol (e.g., Soma®) within 24 hours of screening